Blanco-Ruiz, MarinaAmaya-Pascasio, Laurade Torres Chacon, ReyesJosefa Alvarez Soria, MariaArjona-Padillo, AntonioCarrillo Bailen, Maria MagdalenaMilan Pinilla, RodrigoPerez Ortega, IreneSanchez Rodriguez, BelenAndrade Zumarraga, LuisValverde Moyano, RobertoPayan Ortiz, ManuelCastillo Fernandez, Alba MariaDel Toro Perez, CristinaGonzalez Bustos, PabloAguera Morales, EduardoSanchez Lopez, PurificacionHidalgo Martin, BeatrizRoa Chamorro, RicardoFernandez Perez, JavierMejias Olmedo, Maria VictoriaMartinez-Sanchez, Patricia2025-01-072025-01-072021-11-01https://hdl.handle.net/10668/24985Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine clinical practice have been conducted to analyse and compare the efficacy and safety of the two drugs. Methods: Retrospective observational study of patients treated with a PCSK9 inhibitor in five hospitals in Andalusia (southern Spain). Baseline demographic and clinical data, LDL-cholesterol levels and the occurrence of MACEs during the follow-up period were recorded. Results: A total of 141 patients were included in the study: 90 were treated with alirocumab and 51 with evolocumab. The patients' mean age (IQR) was 58 (11) years and 58 (41%) were women. The most frequent concomitant medications were statins, 94 (66.7%), followed by antiplatelet therapy (66%) and ezetimibe (65.2%). The median (IQR) follow-up period was 18 (18) months, with 18 (24) for alirocumab and 11 (18) for evolocumab. At the six-month follow-up visit, LDL-cholesterol values had decreased to pre-treatment levels and remained significantly decreased (penAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/EvolocumabAlirocumabPCSK9iHypercholesterolemia familiarCardiovascular diseaseStatins intoleranceHeterozygous familial hypercholesterolemiaStatin therapyDouble-blindEvolocumabManagementEzetimibeTrialresearch article36643997open access10.1016/j.athplu.2021.08.0092667-0895https://doi.org/10.1016/j.athplu.2021.08.009787134700005